Taboo Cognition, Tetlock

From Philip Tetlock (2003) paper on Taboo Cognition: Thinking the unthinkable: sacred values and taboo cognitions.

Many people insist that their commitments to certainvalues (e.g. love, honor, justice) are absolute and inviol-able – in effect, sacred. They treat the mere thought oftrading off sacred values against secular ones (such as money) as transparently outrageous – in effect, taboo. Economists insist, however, that in a world of scarce resources, taboo trade-offs are unavoidable. Researchs hows that, although people do respond with moraloutrage to taboo trade-offs, they often acquiesce whensecular violations of sacred values are rhetorically reframed as routine or tragic trade-offs. The results reveal the peculiar character of moral boundaries onwhat is thinkable, alternately punitively rigid and forgivingly flexible.

This article summarizes an emerging body of research that explores how people cope – cognitively and emotionally –with a fundamental contradiction of social life. The contradiction can take diverse forms but its canonicalform can be stated simply.

On the one hand, as economistsfrequently remind us, we live in a world of scarce resources in which, like it or not, everything must ultimately take onan implicit or explicit price. Indeed, this austere insight prompted Oscar Wilde to define an economist as someonewho knows the price of everything and the value ofnothing.

On the other hand, sociological observers pointout that people often insist with apparently great conviction that certain commitments and relationships aresacred and that even to contemplate trade-offs with the secular values of money or convenience is anathema. In the social world inhabited by most readers of this journal, to be caught calculating the opportunity costs of one’s family or professional integrity or loyalty to one’s country is to reveal that one ‘just does not get it’ – that one simply does not understand what it means to participate in these rule-governed forms of social life in the roles of parent/spouse, scientist or citizen.

When economic necessity collides with cultural-identityand moral-religious imperatives, and in the modern world such collisions are common, the resulting dissonance can be excruciating.

Finite resources sometimes require placing at least implicit dollar valuations on a host of things that society at large, or vocal ideological sub-cultures, adamantly declare non-fungible: human life (what price access to medical care?), justice (what price access to legal representation?), preserving natural environments (what price endangered species?), and civilliberties and rights (can ethnic – religious profiling toidentify terrorists be justified on Bayesian and cost –benefit grounds?).

This article explores these issues in two sections. The first section offers a working definition ofsacred values and a set of hypotheses concerning howpeople cope with secular encroachments on such values. The second section sketches the principal lines of empiricalwork bearing on these hypotheses.

Conceptual backdrop

Political philosophers – from Aristotle to Marx and Nietzsche – have long speculated that citizens are morelikely to do what they are supposed to do if they believe themoral codes that regulate their lives are not arbitrarysocial constructions but rather are anchored in bedrock values that transcend the whims of mere mortals. ‘Don’t do x because I say so’ has less impact than ‘don’t do x because God says so’. By the middle of the 20th century, prominent anthropologists and sociologists had made the complementary observation that, although there is vast variation inwhat groups hold sacred, sacredness seems to qualify as afunctional universal across societies, both primitive and modern, and that moral communities erect a variety of psychological and institutional barriers to insulate sacredvalues from secular contamination.To jumpstart social-cognitive research on this topic,T etlocket al. defined sacred values as those values that a moral community treats as possessing transcendental significance that precludes comparisons, trade-offs, orindeed any mingling with secular values. Of course, the policy a community proclaims towards a sacred valuerepresents an expressed, not a revealed, preference. Our actual choices may belie our high-sounding proclamations that we have assigned infinite weight to the sacred value.

Tetlock et al. advanced a sacred value protectionmodel (SVPM) that asserted that, when sacred valuescome under secular assault, people struggle to protecttheir private selves and public identities from moral contamination by the impure thoughts and deeds impliedin the taboo proposals. The SVPM can be captured in three interrelated sets of propositions: moral-outrage hypotheses, moral-cleansing hypotheses, and reality-constraint hypotheses.

… to conclude:

…Intuitive theologians are suspicious, and unapologetically so, of the classic Enlightenment values of open-minded inquiry and free markets. Opportunity costs be damned, some trade-offs should never be proposed, some statistical truths never used, and some lines of causal/counterfactual inquiry never pursued.

More available here and Tetlock’s site here.

A blog on his Superforecasting ideas here and putting the ideas into practise on judging success of biopharma drugs here.

Time to Build and why we are not…

From legendary VC, founder and Silicon Valley pioneer Marc Andreessen in a viral essay with a simple call to arms: it’s time to build. Taking the moment turning in its head and flipping the VC critiques of “go fast breaks things” into why is everyone so slow.... thought provoking wherever you sit on investment or political spectrum. … Essay here.

And Ezra Klein on a commentary essay lays the blame not on ideas or ambition but on the log jams that are US institutions and politics. His companion commentary here.


Michael Liebreich on climate post-COVID

Michael Liebreich on climate post-COVID: "...Epidemics are not the only systemic risks to which we have been oblivious. In the run-up to the Great Financial Crisis we were oblivious to the systemic risks to our financial system posed by extreme levels of leverage and risky, opaque derivatives. And most people are still complacent about the systemic risks to our planetary environment posed by thoughtless economic development. Is it fanciful to hope that that as a result of Covid-19 the world pays a bit more attention to those urging us to respect our planetary boundaries, and a bit less to those pretending they do not exist?

In summary: Covid-19 is causing a massive drop in emissions this quarter, perhaps as much as 20%; after that, emissions will rebound, but remain significantly down until a vaccine enables a full recovery; even after that, they may well remain depressed for some years by an economy again hobbled by a colossal mountain of debt; and in the longer term, the stickiness of some of the new behavior, business models and technologies will certainly accelerate the transition to a low-carbon economy. Out of this terrible period, some good will come..." 4 min op-ed piece for BNEF here.

Policy Idea: Regulators Could Allow Early Use of COVID-19 Vaccine or Treatment

My paper was accepted by the Mercatus Center at George Mason University:

Quickly developed therapeutic, prophylactic, and vaccine treatments will be essential to defeat the COVID-19 pandemic. Standard regulatory and development protocols typically yield drug development in 6 to 11 years. However, experimental vaccines and prophylactics against COVID-19 are in development and currently in trials, making deployment after safety trials feasible within months. Though efficacy of these treatments is uncertain, with probability of success, on average, at just 16 percent, efficacy can still be tested in real-world settings by adopting an approach that allows patients to begin drug treatments earlier in the regulatory process.

After phase I trials have been completed and data have been gathered, an expert committee should be convened to advise on the risk, benefit, and chance of success of the novel agent with a view toward distribution to the public through patient choice. There is limited downside risk and a good chance of a positive outcome with this approach. The US Food and Drug Administration (FDA) has the authority to approve pharmaceuticals requiring further trials, but the success of this approach will depend on coordination between sponsoring research organizations, trial designers, and regulators. International pharmaceutical regulators, such as those in the United Kingdom, Europe, or Japan, can also adopt this approach.

At this point, a clear indication of regulators’ openness to this approach would provide certainty for organisations and accelerate development of possible vaccines and treatments. When adjusting for probability, this approach may save hundreds of thousands of lives in the United States and more globally.

More here at this link at Mercatus. Or full PDF here.

Under a traditional approach, a 50 person phase I trial might not be considered enough data to make strong judgments on safety and efficacy. It’s considered exploratory. However imagine…

10 separate Phase I trials (or trials with adaptive design) start in April 2020 across multiple countries. Patient numbers and characteristics (eg age, presence of COVID-19 antibodies, sex) are careful considered. The statistical power of multiple trials is stronger than one or two trials. 10 trials of n = 50 (say, up to 100) could be run in US, China, Italy, UK, Germany, France, South Korea to name a few countries with R&D capabilities with either commercial or non-profit led organisations that could run such trials. Results could be available in July. These data would include safety data, and preliminary measurements of efficacy such as COVID-19 antibodies.

Each interested country could convene its own expert and stakeholder committee. That committee could vote on if tentative approval should be given based on a benefit and risk assessment of the data. This meeting should be held in public and take submissions from stakeholders potentially replicating FDA advisory committee meeting processes or similar. A citizen’s jury process could run given the state of public interest.  

In an optimistic scenario of no safety signals and strong efficacy signals, this would allow a September 2020 launch with high risk populations such as over-65s and healthcare workers prioritised. This is subject to commercial scale up of manufacturing. Funding for this should be given in April in hope of a positive scenario. In a pessimistic scenario, negative safety signals would not warrant tentative approval. The downsides would be limited to the volunteer trial participants and the investments taken.

The cost of running 10x phase I/II trials now is perhaps between $200m to $1bn. Given that this could solve the problem - it seems to be something that governments should be doing or incentivising. Especially vs fiscal bail outs wheich are 1000x this amount.

Now the data might come back negative - in which case there is no quick vaccine. But, if there were very strong efficacy signals and no safety signals then this should be something for governments and regulators to consider.